In early 2025, MHRP launched its first study in the Eastern European country of Georgia to characterize HIV risks, molecular epidemiology and related infections. As part of the study, MHRP is working closely with WRAIR’s forward directorate in Tblisi, WRAIR-Europe-Middle East, and the Tengiz Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center.
Researchers with MHRP’s B cell immunology lab are working to screen hundreds of samples from the program’s African Cohort Study (AFRICOS) to identify and isolate the next generation of potent, broadly neutralizing antibodies (bNAbs) that have potential to prevent or treat new and evolving strains of HIV.
As we reflect on 2024, MHRP at Walter Reed Army Institute of Research celebrates the power of collaboration in driving HIV research forward. Through our international partnerships with scientists, healthcare professionals and communities, we’re one step closer to a future without HIV.
MHRP's African Cohort Study (AFRICOS), is a longitudinal observational cohort study that is able to answer key questions surrounding people living with HIV in sub-Saharan Africa. The AFRICOS team worked with the Global Health Security and Diplomacy (GHSD) U.S. President's Emergency Plan for AIDS Relief (PEPFAR) Ambassador Dr. John Nkengasong and Chief Science Officer, Dr. Mike Reid, to develop and publish a manuscript summarizing key findings and highlighting the transformative impact of this cohort and how AFRICOS has contributed to the HIV 95-95-95 goals in sub-Saharan Africa.
